



**101 Federal Street, Suite 1900 #10
Boston, Massachusetts 02110-1821
508-865-8907**

info@eclinicalresearchconsulting.com
<http://www.eclinicalresearchconsulting.com>

Clinical Research Education Program Agenda

(rev. August, 2006)

CLINICAL RESEARCH EDUCATION PROGRAM
Program Agenda

DAY ONE

- I. Introductions 9:00am – 9:15am
- II. The Drug Development Process 9:15am – 10:00am
1. Types of Research
 2. Clinical Research: How Do We Accomplish this Goal?
 3. Phases of Clinical Research
 4. Common Obstacles
- III. Principal Investigator Responsibilities 10:00am – 10:30am
1. What is a Principal Investigator (PI)?
 2. FDA Form 1572
 3. GCP Guidelines for Investigators
- BREAK 10:30am – 10:45am
- IV. FDA Regulations in Clinical Research 10:45am – 12:00pm
Title 21 CFR – Food and Drug Administration

Reviewed Parts

1. CFR Part 11: Electronic Records; Electronic Signatures
2. CFR Part 50: Protection of Human Subjects
3. CFR Part 54: Financial Disclosure by Clinical Investigators
4. CFR Part 56: Institutional Review Boards
5. CFR Part 312: Investigational New Drug Application
6. CFR Part 812: Investigational Device Exemptions
7. CFR Part 814: Premarket Approval of Medical Devices
8. HIPPA: Guidelines and Requirements

Parts Not Reviewed

1. CFR Part 314: Application for FDA Approval to Market A New Drug
2. CRF Part 320: Bioavailability and Bioequivalence Requirements
3. CFR Part 601: Licensing

- V. ICH Guidelines for Good Clinical Practice 12:00am – 12:15am
1. What Is GCP and How Do They Differ from FDA Regulations?
- VI. Informed Consent 12:15am – 1:00pm
1. What is Informed Consent?
 2. FDA Requirements (Sample ICF Review)
 3. Developing an Informed Consent Form

- | | | |
|-------|---|-----------------|
| | LUNCH | 1:00pm – 2:00pm |
| VII. | The Clinical Research Protocol | 2:00pm – 2:45pm |
| | 1. FDA/GCP Requirements | |
| | 2. Working with the Clinical Research Protocol | |
| | 3. Protocol Deviations | |
| | 4. Protocol Compliance | |
| | 5. Creating Tools that Aid in Protocol Adherence | |
| VIII. | Understanding Adverse Events | 2:45pm – 3:15pm |
| | 1. What is an Adverse Event? | |
| | 2. What is a Serious Adverse Event? | |
| | 3. Documenting and Reporting Adverse Events | |
| IV. | Source Documentation | 3:15pm – 3:30pm |
| | 1. What are Source Documents? | |
| | 2. Examples of Source Documents Used in Clinical Research | |
| | 3. How to Maintain Adequate Source Documentation | |
| | 4. What are Sponsor Companies Looking For? | |
| | BREAK | 3:30pm – 3:45pm |
| IX. | Essential Documents | 3:45pm – 4:00pm |
| | 1. What are Essential Documents? | |
| | 2. FDA/GCP Regulatory Requirements | |
| | 3. Maintaining Essential Documents | |
| | 4. Communicating and Corresponding with the IRB | |
| X. | Non-Compliance, Fraud and FDA Suspension | 4:00pm – 4:30pm |
| XI. | The Role of the Clinical Research/Data Coordinator | 4:30pm – 5:00pm |
| XI. | Questions, Discussion | 5:00pm |

DAY TWO

- | | | |
|-----|---|------------------|
| I. | Completing the Case Report Form/Data Collection | 8:00am – 9:00am |
| | 1. General Requirements | |
| | 2. Case Report Form Guidelines | |
| | 3. Case Report Form Review | |
| | 4. Checks and Balances | |
| II. | Audits | 9:00am - 10:00am |